Larson Financial Group
HUMA icon

Larson Financial Group’s Humacyte HUMA Stock Holding History

Larson Financial Group’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6 Hold
12
– – ﹤0.01% 3841
2026
Q2 		$9 Hold
12
– – ﹤0.01% 3734
2026
Q1 		$7 Hold
12
– – ﹤0.01% 3612
2025
Q4 		$12 Hold
12
– – ﹤0.01% 3423
2025
Q3 		$21 Buy
+12
New +$24 ﹤0.01% 3393

Other funds holding HUMA

Antipodes Partners
Antipodes Partners Royal Exchange, Australia $5.43B AUM 15.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Endowment Wealth Management
Endowment Wealth Management Appleton, Wisconsin $292M AUM 11.49% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Wealth Effects
Wealth Effects Boston, Massachusetts $370M AUM 63.53% 1-Year Est. Return
LJI Wealth Management
LJI Wealth Management Indianapolis, Indiana $712M AUM 13.75% 1-Year Est. Return
United Asset Strategies
United Asset Strategies Garden City, New York $1.46B AUM 24.51% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Miramontes Capital
Miramontes Capital Newport, California $331M AUM 19.33% 1-Year Est. Return

Larson Financial Group's HUMA Position: Q3 2026 in Review

Larson Financial Group held its Humacyte (HUMA) position steady in Q3 2026 at 12 shares worth $6. The position accounts for ﹤0.01% of the portfolio, ranked #3841.

Larson Financial Group first reported a position in HUMA in Q3 2025 and has held it in 5 quarters since. The position peaked at $21 in Q3 2025. 63 funds tracked by Wall St. Rank hold HUMA as of Q3 2026.

  • Larson Financial Group held 12 shares of Humacyte worth $6 as of Q3 2026.
  • Larson Financial Group left its Humacyte share count unchanged in Q3 2026.
  • Humacyte made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #3841 holding.
  • Larson Financial Group first reported a position in Humacyte in Q3 2025 and has held it in 5 quarters since.
  • Larson Financial Group's Humacyte position peaked at $21 in Q3 2025.
  • 63 funds tracked by Wall St. Rank held Humacyte as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.